Owlstone Medical

Owlstone Medical has developed a breath analyzer for disease detection, focusing on non-invasive diagnostics for cancer, inflammatory diseases, and infectious diseases. The company’s BreathBiopsy® platform introduces a new diagnostic modality that uses breath analysis for precision medicine and early disease detection. It employs proven microchip chemical sensor technology (FAIMS) to analyze volatile organic compounds (VOCs) present in breath to detect disease biomarkers. The Breath Biopsy platform can be used for clinical diagnosis and precision medicine, with applications spanning cancer and a wide range of other medical conditions. These tests are highly sensitive and selective, enabling early diagnosis when treatment is more effective and lives can be saved.Owlstone Medical is currently developing tests for lung cancer and colorectal cancer (the two most common cancer killers globally) as well as asthma stratification by treatment response. The company also provides Breath Biopsy products and services to academic, clinical, and pharmaceutical partners who wish to develop breath-based diagnostic assays for their own applications.